ReviewFrontiers in pharmacology2021
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Anticoagulation approaches in hemodialysis: a systematic review of efficacy, safety, and literature gap.International urology and nephrology · 2026Pooled it
- The Impact of NOACS versus VKAS on Absolute and Relative Cognitive Function Decline Over Time: A Machine Learning Approach.Thrombosis and haemostasis · 2026Observational
- Advances in the Diagnosis and Management of Acute Coronary Syndrome: A Clinical Review.Cureus · 2026Review
- Prognostic role of the 2MACE score in older patients with atrial fibrillation.Internal and emergency medicine · 2026Observational
- Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001.Research and practice in thrombosis and haemostasis · 2026Article
- Albumin level and risk of major bleeding in patients with atrial fibrillation on direct oral anticoagulants.European heart journal. Cardiovascular pharmacotherapy · 2025Observational
- Prognostic role of short physical performance battery in elderly hospitalized atrial fibrillation patients.Internal and emergency medicine · 2025Article
- Predicting drug-drug interactions and optimal dosing of betrixaban with physiologically based pharmacokinetic modeling in patients with renal impairment who were coadministered with P-glycoprotein inhibitors.The Journal of international medical research · 2025Article
- Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review.Clinical pharmacokinetics · 2025Review
- Bridging the Gaps in Atrial Fibrillation Management in the Emergency Department.Journal of cardiovascular development and disease · 2025Review
- A real-world safety evaluation of new oral anticoagulants in elderly patients: evidence from the Adverse Drug Reaction Monitoring Center of Henan Province.Journal of pharmaceutical policy and practice · 2025Article
- Contemporary approaches in the peri-endoscopic management of antithrombotic agents: current paradigms, challenges, and prognostications.Therapeutic advances in gastroenterology · 2025Review
- Emerging Biomarkers for Assessing Thrombotic Risk in Patients Receiving Direct Oral Anticoagulants (DOACs).Cardiovascular & hematological agents in medicinal chemistry · 2025Review
- Direct-Acting Oral Anticoagulant Dabigatran as a Bridging Therapy while Optimizing Warfarin Dosage for Cardioembolic Stroke.Cerebrovascular diseases extra · 2025Article
- Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting.Cancer reports (Hoboken, N.J.) · 2025Article
- Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster.European journal of heart failure · 2024Review
- Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing.Blood advances · 2024Article
- Efficacy and safety of direct oral anticoagulants versus warfarin in the treatment of cerebral venous sinus thrombosis.Acta neurologica Belgica · 2024Article
- The Role of the Pharmacist in a Patient's Care for Individuals Undergoing Anticoagulant Therapy: A Case Report.Life (Basel, Switzerland) · 2024Article
- Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement.ESC heart failure · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to prevent and treat venous thromboembolism. Despite their widespread use in clinical practice, there are still some unresolved issues on optimizing their use in particular clinical settings. Herein, we reviewed the current clinical evidence on uses of DOACs from pharmacology and clinical indications to safety and practical issues such as drugs and food interactions. Dabigatran is the DOAC most affected by interactions with drugs and food, although all DOACs demonstrate a favorable pharmacokinetic profile. Management issues associated with perioperative procedures, bleeding treatment, and special populations (pregnancy, renal and hepatic impairment, elderly, and oncologic patients) have been discussed. Literature evidence shows that DOACs are at least as effective as VKAs, with a favorable safety profile; data are particularly encouraging in using low doses of edoxaban in elderly patients, and edoxaban and rivaroxaban in the treatment of venous thromboembolism in oncologic patients. In the next year, DOAC clinical indications are likely to be further extended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.